Skip to main content

Table 1 In vitro efficacy of fidaxomicin and ribavirin against 2 different ZIKV strains in 4 different cell lines

From: Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus

ZIKV strain

Cell line

Fidaxomicin

Ribavirin

EC50 (μM)a

EC90 (μM)b

CC50 (μM)c

EC50 (μM)a

EC90 (μM)b

CC50 (μM)c

ZG-01

Vero

11.7 ± 2.1

48.2 ± 5.3

126.0 ± 10.3

> 100

> 100

485.5 ± 20.1

SNB19

6.0 ± 1.0

8.9 ± 0.6

113.7 ± 9.9

> 100

> 100

478.2 ± 17.2

Huh7

7.7 ± 1.7

17.8 ± 3.5

76.4 ± 5.8

12.7 ± 2.3

54.3 ± 3.5

491.8 ± 19.4

A549

12.2 ± 3.6

39.5 ± 4.8

135.8 ± 12.1

33.2 ± 3.4

71.6 ± 6.2

170.1 ± 25.9

MR766

Vero

12.4 ± 3.0

45.2 ± 6.2

126.0 ± 10.3

> 100

> 100

485.5 ± 20.1

SNB19

6.8 ± 1.2

9.5 ± 1.5

113.7 ± 9.9

> 100

> 100

478.2 ± 17.2

Huh7

7.3 ± 2.5

16.2 ± 3.9

76.4 ± 5.8

15.6 ± 2.1

58.3 ± 3.2

491.8 ± 19.4

A549

13.0 ± 4.4

42.2 ± 4.6

135.8 ± 12.1

35.2 ± 5.2

74.6 ± 8.5

170.1 ± 25.9

  1. aThe 50% effective concentration, or the concentration necessary to reduce viral yield by 50%, was determined using a plaque assay
  2. bThe 90% effective concentration, or the concentration necessary to reduce viral yield by 90%, was determined using a plaque assay
  3. cConcentration required to inhibit the cell growth by 50% in the absence of virus